Ituran Location and Control Ltd.

Now is a good time to buy shares of Ituran Location and Control, a U.S.-listed Israel-based small-cap provider of satellite-based transportation monitoring services, Freedom Broker says. Over the last three weeks, its stock price has <a href="https://finance.yahoo.com/quote/ITRN/">fallen</a>&nbsp;nearly 17%. But this is temporary, Freedom Broker thinks, with the selloff opening opportunities to build up a long position.

Freedom Broker likes telematics company Ituran on dip, says 'buy' on 2-month horizon

C3.ai, Inc.

The company must prove it can return to sustainable growth

Motley Fool says wait to buy small-cap AI software maker C3.ai after off earnings

AMREP Corporation

Freedom Broker calls AMREP Corporation an attractive speculative idea for investors seeking exposure to a rising U.S. mortgage market. The small-cap landowner and residential real estate developer from New Mexico is expected to release a positive quarterly earnings report this week, Freedom Broker analysts said. This could give a boost to the company’s shares of 10-20%.

Freedom Broker short-term trade idea: Buy AMREP stock to bet on U.S. mortgage market

Innodata Inc.

Alphabet Inc.

<i>Barron's </i><a href="https://www.barrons.com/articles/innodata-stock-pick-ai-model-training-data-accuracy-2ee4d5a8?mod=hp_STOCKPICKS_2">writes</a>&nbsp;that investors should buy shares of Innodata, a small-cap provider of data solutions for developing generative AI models. The company’s stock has surged more than <a href="https://finance.yahoo.com/quote/INOD/">11-fold</a>&nbsp;over the last three years, yet things are “just getting started,” the publication believes. With AI adoption accelerating, companies are in growing need of high-quality data sets.

Barron’s: Google partner Innodata surged 11x in 3 years, is 'just getting started'

e.l.f. Beauty, Inc.

Coty Inc.

Now may be a good time to buy shares of mid-cap cosmetics company e.l.f. Beauty, <i>Barron's&nbsp;</i><a href="https://www.barrons.com/articles/buy-elf-beauty-stock-price-pick-cafe1c92?mod=RTA">writes</a>. The stock has fallen 40% from its 2024 peak, even though the company is generating sales at double the industry’s growth rate and beat earnings estimates in the second quarter for the seventh time in eight quarters.

Barron’s: Buy e.l.f. Beauty on the dip with its 2x industry sales growth 

American Eagle Outfitters, Inc.

Shares of jeans maker American Eagle Outfitters <a href="https://finance.yahoo.com/quote/AEO/">soared</a>&nbsp;in the first minutes of morning trading today, September 4, rising nearly 24%. The company <a href="https://investors.ae.com/press-releases/news-details/2025/AEO-Inc--Reports-Second-Quarter-Fiscal-2025-Results/default.aspx">reported</a>&nbsp;its second-highest quarterly revenue ever, while profitability <a href="https://www.cnbc.com/2025/09/03/american-eagle-outfitters-aeo-earnings-q2-2025.html">beat</a>&nbsp;analyst forecasts. This was thanks in part to a controversial advertising campaign featuring Hollywood actress Sydney Sweeney.

Shares of American Eagle soar after earnings beat, boosted by Sydney Sweeney ad

Chart Industries, Inc.

Lumen Technologies, Inc.

Badger Meter, Inc.

The second quarter opened with a rout after U.S. President Donald Trump announced his tariff plan on April 3, with tariffs to be raised several dozen percentage points. The S&amp;P 500&nbsp;<a href="https://www.reuters.com/markets/sp-500-loses-24-trillion-market-value-biggest-one-day-loss-since-2020-2025-04-03/#:~:text=April%203%20(Reuters)%20%2D%20S%26P,tailspin%20on%20March%2016%2C%202020.">erased</a>&nbsp;$2.4 trillion in value in a single day, the steepest one-day loss since the pandemic. Small-cap stocks were hit harder by the selloff. Between April 2 and April 8, the small- and mid-cap Russell 2000 plunged 14%, versus a 12% decline in the large-cap S&amp;P 500.

Freedom Finance Global: Hedge funds trim health care, add to cyclicals and tech in 2Q

Frontier Group Holdings, Inc.

Low-cost carrier Frontier Airlines, with a market <a href="https://finance.yahoo.com/quote/ULCC/">capitalization</a>&nbsp;of $1.28 billion on the Nasdaq, could be “the biggest beneficiary” of peer Spirit Airlines’ bankruptcy, Deutsche Bank <a href="https://www.marketwatch.com/story/spirit-airlines-is-going-bankrupt-this-rival-is-already-reaping-the-benefits-a7f12beb?mod=newsviewer_click_seemore">says</a>. That prompted the bank to take the “relatively rare step” of upgrading its price target on Frontier Airlines shares as it upgraded their rating, MarketWatch noted. Spirit filed a new bankruptcy petition in late August – its second in the past year.

A 'rare step': Deutsche Bank upgrades Frontier Airlines and doubles target price

Ionis Pharmaceuticals, Inc.

Quotes of biotech Ionis Pharmaceuticals jumped 35% in a single day after it announced a successful trial of a drug that reduces triglyceride levels in the blood and prevents cases of acute pancreatitis. Analysts were positive about the results. The company, which is known for its Spinraza drug for spinal muscular atrophy, could see its shares rise another 40%, according to some analysts' models.&nbsp;

Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug

SentinelOne, Inc.

Palo Alto Networks, Inc.

CrowdStrike Holdings, Inc.

The Motley Fool has <a href="https://www.fool.com/investing/2025/09/02/1-no-brainer-ai-stock-down-75-buy-dip-wall-street/">spotlighted</a>&nbsp;mid-cap cybersecurity company SentinelOne as a "no-brainer" AI stock to buy while on the dip. It still trades far below its 2021 high and at some of the cheapest valuations in its sector, even though the company is expanding faster than peers.

Motley Fool spotlights cybersecurity firm SentinelOne as AI stock to buy on the dip

Scholar Rock Holding Corporation

Biogen Pharmachem Industries Ltd

Freedom Broker has issued a short-term trade idea to buy shares of biotech company Scholar Rock ahead of a U.S. regulator’s ruling on the registration of its drug for spinal muscular atrophy (SMA). If approved, analysts said, apitegromab could mark a new era in neuromuscular disease therapy and drive a nearly 40% rise in the stock over the next two months.

SMA drugmaker Scholar Rock may jump on upcoming FDA decision, Freedom Broker thinks

GitLab Inc.

It sees almost 50% upside versus current market quotes on the stock

Small caps